Sign In
Buy VNDA
$6.09
-0.0400 (-0.653%)
At Close: Jun 03, 2026
VNDA ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Vanda Pharmaceuticals Inc. Shareholders Who Lost Money
07:25am, Tuesday, 01'st Oct 2024
NEW YORK, NY / ACCESSWIRE / October 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ:VNDA) conc
NEW YORK, NY / ACCESSWIRE / September 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ:VNDA) c
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ:VNDA) c
Vanda Pharmaceuticals Inc. Being Investigated on Behalf of Vanda Pharmaceuticals Inc. Investors. Contact Levi & Korsinsky For Details.
07:25am, Thursday, 26'th Sep 2024
NEW YORK, NY / ACCESSWIRE / September 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ:VNDA) c
NEW YORK, NY / ACCESSWIRE / September 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ:VNDA) c
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Vanda Pharmaceuticals Inc. (VNDA)
07:30am, Tuesday, 24'th Sep 2024
NEW YORK, NY / ACCESSWIRE / September 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ:VNDA) c
Vanda Pharmaceuticals Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - VNDA
07:20am, Monday, 23'rd Sep 2024
NEW YORK, NY / ACCESSWIRE / September 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ:VNDA) c
VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis
12:41pm, Friday, 20'th Sep 2024
The FDA issues a complete response letter to Vanda's new drug application for tradipitant for treating symptoms in gastroparesis.
NEW YORK, NY / ACCESSWIRE / September 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ:VNDA) c
Why Vanda Pharmaceuticals Stock Sank by Nearly 6% Today
05:20pm, Thursday, 19'th Sep 2024
The biotech had discouraging news to report about one of its pipeline drugs. The FDA declined to approve its application.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
02:45pm, Thursday, 19'th Sep 2024
NEW YORK, NY / ACCESSWIRE / September 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ:VNDA). Such investors are
FDA Strikes Off Vanda Pharmaceuticals' Tradipitant For Stomach Paralysis, Asks For Additional Studies
10:33am, Thursday, 19'th Sep 2024
Thursday, the FDA declined to approve Vanda Pharmaceuticals Inc.'s VNDA New Drug Application (NDA) of tradipitant for symptoms in gastroparesis, providing Vanda with a Complete Response Letter (CRL)
U.S. FDA declines to approve Vanda's stomach paralysis drug
07:57am, Thursday, 19'th Sep 2024
The U.S. Food and Drug Administration has declined to approve Vanda Pharmaceuticals' drug to treat stomach paralysis symptoms, the company said on Thursday.
FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis
07:00am, Thursday, 19'th Sep 2024
WASHINGTON , Sept. 19, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its tradipitant development program.
Vanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare Conference
05:00pm, Wednesday, 11'th Sep 2024
WASHINGTON , Sept. 11, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the 2024 Cantor Global Healthcare Conference in New
